Octreotide cholelithiasis with

Patients using octreotide may develop cholelithiasis or, with prolonged high dosages, hypothyroidism. 

Because octreotide inhibits many other gastrointestinal hormones, it has a variety of intestinal side effects. With prolonged use, gallbladder and biliary tract complications such as cholelithiasis have been reported. About 5% to 10% of patients complain of nausea, diarrhea, and abdominal pain. Local injection pain occurs with about an 8% incidence. With high doses, octreotide may reduce dietary fat absorption, leading to steatorrhea. 

Observational studies Long-term octreotide LAR has been studied in 108 patients with midgut neuroendocrine tumors who were followed for 8 years [75 ]. Patients were followed at 6-monthly intervals and seven developed asymptomatic cholelithiasis (average time after the start of treatment 26 months). The rest of the adverse events occurred within 3 months of the start of therapy. Four patients developed severe reactions (an anaphylactic rash, severe abdominal pain, increased diarrhea, and bradycardia) to the test dose of subcutaneous octreotide and were excluded from the study 28 developed steatorrhea, which resolved after the introduction of pancreatic enzyme supplements. Six patients reported... 

---